- Home
- NRIX
as of 01-20-2026 9:43am EST
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 1.7B | IPO Year: | 2020 |
| Target Price: | $29.08 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.18 - $22.50 | Next Earning Date: | 02-12-2026 |
| Revenue: | $83,687,000 | Revenue Growth: | 48.32% |
| Revenue Growth (this year): | 59.4% | Revenue Growth (next year): | -35.58% |
Stock Insider Trading Activity of Nurix Therapeutics Inc. (NRIX)
Chief Legal Officer
Avg Cost/Share
$18.21
Shares
3,760
Total Value
$67,314.32
Owned After
51,097
Chief Legal Officer
Avg Cost/Share
$17.07
Shares
37,600
Total Value
$641,696.64
Owned After
51,097
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$12.56
Shares
6,284
Total Value
$78,931.44
Owned After
37,592
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$12.80
Shares
3,130
Total Value
$40,053.67
Owned After
37,592
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$12.80
Shares
4,087
Total Value
$52,300.11
Owned After
76,751
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$12.80
Shares
3,644
Total Value
$46,631.17
Owned After
51,097
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ring Christine | NRIX | Chief Legal Officer | Dec 18, 2025 | Sell | $18.21 | 3,760 | $67,314.32 | 51,097 | |
| Ring Christine | NRIX | Chief Legal Officer | Nov 24, 2025 | Sell | $17.07 | 37,600 | $641,696.64 | 51,097 | |
| van Houte Hans | NRIX | Chief Financial Officer | Nov 3, 2025 | Sell | $12.56 | 6,284 | $78,931.44 | 37,592 | |
| van Houte Hans | NRIX | Chief Financial Officer | Oct 30, 2025 | Sell | $12.80 | 3,130 | $40,053.67 | 37,592 | |
| Hansen Gwenn | NRIX | Chief Scientific Officer | Oct 30, 2025 | Sell | $12.80 | 4,087 | $52,300.11 | 76,751 | |
| Ring Christine | NRIX | Chief Legal Officer | Oct 30, 2025 | Sell | $12.80 | 3,644 | $46,631.17 | 51,097 |
Compare NRIX vs Leading Stocks
See how NRIX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NRIX Nurix Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.